Xenon Pharmaceuticals (XENE) Q2 FY26 earnings call

Xenon Pharmaceuticals reported a productive Q2 FY26, highlighted by significant progress towards the Azetukalner (AZK) NDA submission for focal seizures following a successful pre-NDA meeting with the FDA. The company is also actively expanding AZK's potential into neuropsychiatry with three ongoing Phase 3 studies and advancing its pain pipeline with multiple non-opioid candidates. With a strong cash position extending into 2029, Xenon is transitioning towards becoming a fully integrated commercial-stage neuroscience company.